Serum specimens (n = 2,712) obtained from individuals residing in diverse geographic regions and categorized as seropositive (n = 122), seroindeterminate (n = 523), or seronegative (n = 2,067) for human T-cell lymphotropic virus (HTLV) infection in accordance with U.S. Public Health Service guidelines were retested by recombinant transmembrane protein (rgp2l)-spiked Western immunoblotting. Of the 122 HTLV-positive specimens, those from 85 of 85 (100%) U.S. blood donors, 2 of 2 (100%) Brazilians, 1 of 2 (50%) Indonesians, 14 of 14 (100%) Solomon Islanders, and 18 of 19 (95%) Papua New Guineans reacted with rgp2l, yielding an overall sensitivity of 98% (120 of 122). Specimens from individuals whose infections were confirmed to be HTLV type I or HTLV type II by the polymerase chain reaction assay reacted equally well with rgp2l. Of the 523 HTLV-indeterminate specimens, those from 21 of 379 (5.5%) U.S. blood donors, 3 of 6 (50%) Brazilians, 10 of 23 (44%) Ugandans, 8 of 49 (16%) Indonesians, 4 of 36 (11%) Solomon Islanders, and 5 of 30 (17%) Papua New Guineans reacted with rgp2l. None of these 51 specimens reacted with native gp46 and/or gp61/68 in a radioimmunoprecipitation assay, suggesting a false-positive reaction (9.75%). Of the 2,067 HTLV-negative specimens, 12 reacted with rgp2l, yielding a false-positivity rate of 0.6%. These data indicate that while detection of rgp2l is highly sensitive, it can yield false-positive results. Thus, specimens exhibiting reactivity with rgp2l in the absence of reactivity with native gp46 and/or gp61/68 by Western blot should be tested further by a radioimmunoprecipitation assay to verify HTLV type I or type II infection.
Serum specimens (n = 2,712) obtained from individuals residing in diverse geographic regions and categorized as seropositive (n = 122), seroindeterminate (n = 523), or seronegative (n = 2,067) for human T-cell lymphotropic virus (HTLV) infection in accordance with U.S. Public Health Service guidelines were retested by recombinant transmembrane protein (rgp2l)-spiked Western immunoblotting. Of the 122 HTLV-positive specimens, those from 85 of 85 (100%) U.S. blood donors, 2 of 2 (100%) Brazilians, 1 of 2 (50%) Indonesians, 14 of 14 (100%) Solomon Islanders, and 18 of 19 (95%) Papua New Guineans reacted with rgp2l, yielding an overall sensitivity of 98% (120 of 122). Specimens from individuals whose infections were confirmed to be HTLV type I or HTLV type II by the polymerase chain reaction assay reacted equally well with rgp2l. Of the 523 HTLV-indeterminate specimens, those from 21 of 379 (5.5%) U.S. blood donors, 3 of 6 (50%) Brazilians, 10 of 23 (44%) Ugandans, 8 of 49 (16%) Indonesians, 4 of 36 (11%) Solomon Islanders, and 5 of 30 (17%) Papua New Guineans reacted with rgp2l. None of these 51 specimens reacted with native gp46 and/or gp61/68 in a radioimmunoprecipitation assay, suggesting a false-positive reaction (9.75%). Of the 2,067 HTLV-negative specimens, 12 reacted with rgp2l, yielding a false-positivity rate of 0.6%. These data indicate that while detection of rgp2l is highly sensitive, it can yield false-positive results. Thus, specimens exhibiting reactivity with rgp2l in the absence of reactivity with native gp46 and/or gp61/68 by Western blot should be tested further by a radioimmunoprecipitation assay to verify HTLV type I or type II infection.
Infections with human T-lymphotropic virus types I (HTLV-I) and II (HTLV-II) have been found worldwide by the use of serologic assays (2, 12) . Enzyme immunoassay screening tests designed to detect antibodies to HTLV-I or HTLV-II were licensed by the U.S. Food and Drug Administration in 1988, and all individuals donating whole blood and cellular components in the United States are currently tested for antibodies against HTLV-I or HTLV-II (2, 18) . The criterion for seropositivity, as defined by the U.S. Public Health Service Working Group, states that a serum specimen exhibiting reactivity with p249ag and gp46env and/or gp6l/68env be considered positive for HTLV-I or HTLV-II infection. A combination of Western immunoblotting (WB) and a radioimmunoprecipitation assay (RIPA) has been used to visualize antibody reactivity to gag and env gene products (1, 21) . Subsequent studies have demonstrated that while WB can easily detect antibodies to gag products, it often fails to detect antibodies to env products (1, 5) . In the absence of clear env reactivity in WB, a specimen should be further analyzed by RIPA. While RIPA can easily detect env reactivity, the technique is cumbersome and requires radiolabeled viral proteins, making it unsuitable for routine use in the clinical setting (1, 5) . Because of problems inherent with RIPA, focus has recently turned toward recombinant env proteins that can be added to purified viral lysates in WB assays, thereby increasing the sensitivity of env detection (4, 10, 11) .
Prerequisites for recombinant env proteins used in this setting include the ability to detect both HTLV-I and HTLV-II infections with a reactivity that is highly specific for HTLV-I or HTLV-II and a molecular weight which allows differentiation from native gag and env products in WB. Several recombinant envelope glycoproteins have recently been demonstrated to have differential reactivities with specimens from HTLV-I-and HTLV-II-infected individuals (3, 4, 10, 11, 17) . While most of the external glycoproteins contain type-specific epitopes (3, 11) , transmembrane glycoproteins have been shown to react with sera from individuals infected with either HTLV-I or HTLV-II (10, 17) . Recently, a recombinant construct, rgp21307"440 (rgp2l), encoding a 14-kDa protein was shown to react with specimens from nearly 100% of HTLV-infected individuals in an enzyme immunoassay format (6, 19) . Its low molecular weight makes it readily discernible from native gag and env gene products in WB. Although the addition of rgp2l has resulted in enhanced sensitivity in detecting antibodies to envelope proteins in WB assays, the specificity of such assays still remains to be determined (10) . In the present study, we evaluated the sensitivity and specificity of rgp2l-spiked WB for serum specimens from diverse populations and geographic areas and compared the serologic results with conventional HTLV-I WB and RIPA results. Our data demonstrate that the inclusion of rgp2l results in an enhanced sensitivity of envelope detection for both HTLV-Iand HTLV-II-infected individuals, potentially eliminating the need for RIPA of specimens in which native env is not visible. However, this assay also has a potential to yield false-positive results, particularly for non-U.S. populations, thus limiting its applicability as a confirmatory test.
MATERIALS AND METHODS
Patient population. Serum samples (n = 2,712) previously collected from diverse populations and tested for the presence of HTLV infection were selected. Populations included U.S. Armed Forces blood donors (n = 2,361) screened from March 1989 to April 1991, U.S. intravenous drug abusers (IVDAs) (n = 28) with HTLV-II infections confirmed by serology and a polymerase chain reaction (PCR) (described below), and individuals from serosurveys performed in Sao Paulo, Brazil (n = 50), Kampala, Uganda (n = 54), Lake Lindu, Celebes, Indonesia (n = 71), Solomon Islands (n = 51), and Madang Province, Papua New Guinea (n = 97) ( Table 1) . As determined by conventional HTLV antibody tests, specimens from 122 individuals were seropositive (HTLVPOs), specimens from 523 were indeterminate (HTLVind), and specimens from 2,067 were seronegative (HTLVneg). Of the 122 HTLVP0s individuals, 85 were from the United States and included 57 healthy blood donors and 28 IVDAs. Of the 37 asymptomatic carriers from diverse geographic areas, 2 were from Brazil, 2 were from Indonesia, 14 were from Solomon Islands, and 19 were from Papua New Guinea. Specimens from 96 of the 122 HTLVP0s individuals were additionally tested by PCR to differentiate HTLV-I and HTLV-II. Forty blood donors and 11 Papua New Guineans were confirmed to have HTLV-I infections, and 17 blood donors and 28 IVDAs were confirmed to have HTLV-Il infections (see Table 2 ). The geographic origins of HTLVind and HTLVn,g specimens are given in Table 1 .
Reference HTLV antibody tests. Serum specimens were initially tested for HTLV-I antibodies by a commercial enzyme-linked immunosorbent assay (Dupont, Wilmington, Del.) in accordance with the manufacturer's recommendations. Specimens that were repeatedly reactive were further tested by WB (5) with HuT-102 lysate and by RIPA with HTLV-I-infected MT-2 and HTLV-II-infected Mo-T lysates. Sera found to contain antibodies to at least two HTLV structural gene products (p249ag and gp46env and/or gp6l/ 68"fV) by WB alone or in combination with RIPA were considered positive (HTLVPOS), sera reacting with only gag gene products were considered indeterminate (HTLVind), (8, 9) . The hybridized products were electrophoresed and autoradiographed as described previously (8) . Specimens were classified as HTLV-I or HTLV-II positive on the basis of typespecific amplification of both pol and tax-rex regions.
RESULTS
Sensitivity of rgp2l-spiked HTLV-I or HTLV-II WB. Analysis of HTLV-I-or HTLV-II-positive specimens (n = 122) by rgp2l-spiked WB demonstrated that specimens from 57 of 57 (100%) U.S. blood donors, 28 of 28 (100%) IVDAs, 2 of 2 (100%) Brazilians, 1 of 2 (50%) Indonesians, 14 of 14 (100%) Solomon Islanders, and 18 of 19 (95%) Papua New Guineans demonstrated a strong reactivity with rgp2l (Table 2) . Thus, specimens from 120 of 122 HTLVPOS individuals, including all of the specimens established as HTLV-I (n = 51) and HTLV-II (n = 45) positive, reacted with rgp2l, yielding an overall sensitivity of 98%. Forty-eight percent of the 122 HTLVP°specimens (9 HTLV-I-positive specimens, 42 HTLV-II-positive specimens, and 8 HTLV-I-or HTLV-IIpositive specimens not differentiated by PCR analysis) reacted with only gag gene products and not with gp46enV in standard WB. All of these specimens, which required RIPA for confirmation, were strongly reactive with rgp2l.
Specificity of rgp2l-spiked HTLV-I or HTLV-II WB. Reactivity with rgp2l of HTLVind and HTLV"g sera was analyzed to evaluate the specificity of the recombinant protein assay (Table 3) . Of specimens from the 523 HTLVind individuals, those from 21 of 379 (5.5%) U.S. blood donors, A similar analysis of HTLV,eg specimens demonstrated that only 12 of 2,067 (0.6%) reacted with rgp2l, and 4 of these specimens were further confirmed to be negative by PCR analysis.
DISCUSSION
Serologic confirmation of HTLV-I or HTLV-II infection depends upon the presence of antibodies to both gag and env gene products (1, 2) . While commercially available assays can easily detect antibodies to gag gene products, antibodies to env gene products are not always detectable by WB and require RIPA for their detection, particularly in HTLV-II infection. Recombinant env proteins have recently been combined with native purified viral proteins to increase the sensitivity of env detection (10, 11) . One of the recombinant constructs derived from the transmembrane glycoprotein of HTLV-I (CBC rgp213°7"40) has been used to develop assays that not only yield a higher sensitivity of env detection (10) but also provide an excellent marker for early seroconversion (13) . Indeed, our data indicate that specimens from 98% of HTLVP°0 individuals, 48% of whom required RIPA for confirmation, reacted with rgp2l. These results are in general agreement with those of previous reports in which rgp2l-spiked WB (10) and EIA (6, 19) were capable of correctly identifying nearly 100% of individuals infected with HTLV-I or HTLV-II. The transmembrane proteins of oncogenic retroviruses suppress polyclonal B-cell responsiveness, which may account for the absence of antibody to gp2l in some of our HTLVPOS individuals (14) .
The immunodominance of transmembrane proteins of HTLV has previously been documented (3, 4, 10, 15, 20) , and different recombinant constructs have all been shown to react with 74 to 100% of HTLV-I or HTLV-II specimens. For example, a plasmid, RP-D313 488, encoding a 30-to 32-kDa protein reacted with 74% of HTLV-I-positive specimens (3), and plasmid p2le/gp46, encompassing 50% of gp46 and all of gp2le and encoding a 38-kDa protein, reacted with 95% of HTLV-I-or HTLV-II-positive specimens (4) . Similarly, a polyhedrin fusion protein, C182, encoding the full-length gp2l protein of 23 kDa reacted with 95% of HTLV-I-or HTLV-II-positive specimens (15) . The rgp2l construct used in the present study, CBC rgp21307440, with a deletion of amino acids 314 through 330 for better yields, encodes a 14-kDa protein and has been shown to react with 100% of HTLV-I-or HTLV-II-positive specimens (6, 10, 19) . In addition, because of the low molecular weight of rgp2l, it is readily discernible from native gag and env gene products in WB.
While rgp2l-spiked WB is highly sensitive and may eliminate the need for RIPA for serologic confirmation of HTLV-I or HTLV-II infection, it is extremely important to determine the specificity of this assay. In particular, the transmembrane proteins of the majority of retroviruses are highly conserved (7, 16 Alternatively, as sole reactivity with rgp2l represents one of the patterns seen in early seroconversion (13) , early infection in some of these individuals cannot be ruled out; no follow-up specimens from these individuals were available to test this possibility.
In conclusion, the high sensitivity of rgp21 detection for both HTLV-I-and HTLV-II-positive specimens and the ability of this assay to detect early infection suggest that this protein may be useful as a supplementary test in the HTLV confirmation algorithm as a sensitive screen for env gene products. However, the relatively high false-positivity rate demonstrated in this study, especially for different geographic areas, suggests that the presence of rgp21 reactivity with p249aB alone should not replace the current criteria for HTLV-I-or HTLV-II-seropositivity. Additional tests, such as RIPA, should be used for confirmation when individuals will be informed of their test results. Recently, a recombinant protein, MTA-4, derived from the external glycoprotein was successfully used to detect antibodies in HTLV-Iinfected individuals (11) , and similar approaches have been taken to enhance the detection of HTLV-II infection (4a) . In view of the extremely high sensitivity of rgp21 and its ability to detect early infection (13) , it could be included with other recombinant external envelope proteins for serologic confirmation of HTLV infection.
